Axis Biochemicals (Norway) plans homocysteine test launch:
This article was originally published in Clinica
Executive Summary
Axis Biochemicals (Norway) plans to launch an immunoassay for large-scale routine testing of homocysteine next year. Claimed to be the first of its kind, the test measures homocysteine levels for diagnosis of anaemia and as an indicator of cardiovascular disease risk.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.